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Activation of the renin-angiotensin-aldosterone (RAA)
system plays an important role in increasing the risk of
cardiovascular events. In addition to aggressive
management of the major risk factors for cardiovascular
disease, including dyslipidemia, diabetes, hypertension,
and smoking, the use of angiotensin-converting enzyme
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The Heart Outcomes Prevention Evaluation (HOPE) study demonstrated that the angiotensin-converting
enzyme inhibitor, ramipril, significantly reduces mortality, myocardial infarction and stroke in high-risk
cardiovascular patients, beyond the benefits from blood pressure lowering. The tolerability of ramipril
10 mg/day has been an important concern when applying these results. Following the same criteria as the
HOPE study, we investigated the adverse effects profile and tolerability of 10 mg ramipril in high-risk
patients at our institution. In total, 92 patients with high cardiovascular risk were eligible for this study.
Initially, ramipril was prescribed 2.5 mg orally once daily, and then titrated up to 5.0, 7.5, and 10.0 mg/day
at 1-month intervals. The target maintenance dose was 10 mg/day. All adverse events were recorded during
at least 3 months of follow-up. After 4–6 months of the titration protocol, only 18 patients (25.3%) reached
and remained on ramipril 10 mg/day; 11 (15.5%), 22 (30.9%), and 20 patients (28.2%) remained on
2.5, 5.0, and 7.5 mg/day, respectively. Twenty-one patients (22.6%) had at least one adverse event. Twelve
patients (13.0%) stopped treatment because of adverse effects. A total of 23 episodes of adverse events were
reported, including cough (15.1%), dizziness (6.0%), and hypotension (2.4%). Ramipril was relatively
well tolerated in our study population. However, only one-quarter of our patients reached the target
maintenance dose of 10 mg/day. Dry cough, dizziness, and hypotension were the major side effects. About
15% of our patients discontinued ramipril treatment, which is comparable with previous reports.
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(ACE) inhibitors to block the RAA system also retards the
progression of atherosclerosis and offers benefits and
protection for a broad range of patients with myocardial
infarction, left ventricular systolic dysfunction, diabetes,
and stroke [1–7]. In the Heart Outcomes Prevention
Evaluation (HOPE) study, the additional anti-ather-
othromboic benefits of ramipril were observed even in
patients already receiving treatment with aspirin, ` -blockers,
and lipid-lowering agents. Furthermore, the benefits of
ramipril on mortality, myocardial infarction, stroke, cardiac
arrest, heart failure, and revascularization were demonstrated
beyond blood pressure lowering [8]. The vascular mechanism
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underlying ACE inhibitor use includes antagonizing vaso-
constriction via angiotensin II, proliferation of vascular
smooth muscle cells, rupture of plaques, improving
vascular endothelial function, reducing left ventricular
hypertrophy, and retarding myocyte fibrosis [9,10].
Following publication of the results of the HOPE study
[8], prescriptions for ramipril increased significantly,
as has concern about the safety and tolerability of the
10 mg/day dose [11–13]. The most common adverse
effects of ACE inhibitor use are dry cough, angioedema, and
hypotension. Severe, persistent cough limits the use of ACE
inhibitors in a significant number of patients. It has been
speculated that occurrence of this adverse effect is genetically
predetermined; in particular, variants of the genes encoding
ACE, chymase, and B2-bradykinin receptor have been
implicated [14–16]. The incidence of dry cough in Asians is
15–20% higher than in Caucasians [17].
Therefore, this study investigated the tolerability and
safety of ramipril 10 mg/day in high-risk cardiovascular
patients in Taiwan, following similar criteria to those
used for patient selection in the HOPE study.
PATIENTS AND METHODS
Patients
Men and women aged 55 years or older were eligible for this
study if they had one of the following risk factors for
developing major cardiovascular events: a history of
coronary artery disease, stroke, peripheral vascular disease,
or diabetes plus at least one other cardiovascular risk factor
(hypertension, elevated total cholesterol level, low high-
density lipoprotein (HDL) cholesterol levels, current
smoking, or documented microalbuminuria). Patients with
stabilized heart failure of New York Heart Association
(NYHA) class I to III were also eligible. Exclusion criteria
related primarily to absolute contraindications (e.g.
hypersensitivity to ACE inhibitors), as well as warnings
and precautions for the use of ACE inhibitors, in accordance
with the package insert of Tritace (Aventis Pharma, Lance
Cove, NSW, Australia) in Taiwan. Patients were also
ineligible if they had other medical problems that would
either interfere with participation in the trial or lead to
inability to complete the trial. Exclusion criteria included:
non-stabilized heart failure or clinical NYHA class IV;
hemodynamically significant primary valvular or outflow
tract obstruction (e.g. mitral stenosis, asymmetric septal
hypertrophy or malfunctioning prosthetic valve);
constrictive pericarditis; complicated congenital heart
disease; syncope episode presumed to be a result of
uncontrolled life-threatening arrhythmia; planned cardiac
surgery or angioplasty within 3 months; cor pulmonale;
significant renal disease defined as renal artery stenosis,
creatinine clearance less than 0.6 mL/sec or serum creatinine
greater than 2.0 mg/dL, overt nephropathy (> 1+ proteinuria
on dipstick or urinary albumin excretion > 200 +g/min);
hyperkalemia (potas-    sium > 5.3 mEq/L); any other major
non-cardiac illness expected to reduce life expectancy or
interfere with study participation; and simultaneous
treatment with another experimental drug or ACE inhibitor.
Study protocol
The study was designed to follow each patient for 3 months
after a 10 mg daily dose, or the highest tolerable dose, of
ramipril had been achieved through titration. Ramipril
2.5 mg tablets were supplied by Aventis Pharma, Taiwan.
Patients without a history of heart failure were assigned to
receive ramipril 2.5 mg orally once daily for 1 month, 5 mg
once daily for the next month, 7.5 mg once daily for the third
month, and then the maintenance dose of 10 mg once daily
after the last visit. The tolerability of the study medication
was assessed by reported adverse events and by monitoring
blood cell count, electrolytes, serum creatinine, liver
function, and fasting blood glucose.
If an adverse event occurred, the patient was advised to
downgrade to half of the assigned dose and stay at that
dosage for 2–3 weeks, and then increase to the previous
dose. If the patient was compliant, dose titration was
continued according to the protocol; if not, the patient was
kept on the highest tolerable maintenance dose for 1 month.
For patients switched from other ACE inhibitors to
ramipril, ramipril was titrated in the same steps as described
above. It was understood that treatment with other ACE
inhibitors was to be fully stopped, and treatment with ramipril
started and titrated up to the target dose of 10 mg once daily.
The trial started at Kaohsiung Medical University
Chung-Ho Memorial Hospital in October 2002, and ended
in June 2003.
Statistical analysis
The aim of the study was to collect events when recognized
by the physicians. Therefore, the evaluation variables were
the number of patients who received the 10 mg/daily dose
and the numbers at each highest tolerated dose, the number
of treatment discontinuations (resulting from adverse events
or not), the overall number of adverse events, and the
number of serious adverse events. The analysis of these
observations was purely descriptive. No efficacy variables
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were collected because the necessary observation time would
have to have been several years.
RESULTS
Patient characteristics
A total of 92 patients, 59 males and 33 females, were enrolled
in the study. The baseline characteristics of patients in the
current study are compared with those of patients in the
HOPE study in Table 1. The mean age in this study was
64 (  12.2 years, similar to that in the HOPE trial, but the
mean body mass index (BMI) was higher in the HOPE study
(28.0 ( 4.0) than in our population (25.2 ( 4.5).
There was a significant difference in the prevalence of
cardiovascular risk factors between the two studies. A
larger percentage of females was recruited in our study
than in the HOPE study (35.9% vs 27.5%). There were also
lower percentages of patients with elevated total cholesterol
(43.4% vs 65.4% in HOPE), HDL-cholesterol (26.1% vs
48.1% in HOPE), and a history of coronary artery disease
(38.0% vs 51.9% in HOPE). The percentages of patients
with diabetes and who smoked cigarettes were similar in
the two studies. A higher percentage of patients in our
study were taking concomitant `-blockers, diuretics, and
lipid-lowering agents than in the HOPE study.
Overview of the protocol
Of the 92 study patients, nine dropped out at the patient’s
request or because of a protocol violation, 12 discontinued
treatment due to adverse effects, and 71 patients completed
the study (Table 2).
Compliance
Among the 71 patients who completed the protocol,
18 reached and remained at a dose of 10 mg/day, while
53 remained at a lower dose (Table 2). Eleven, 22, and 20
patients stayed at 2.5, 5.0, and 7.5 mg/day, respectively.
Table 1. Baseline characteristics of study patients compared with those in the HOPE study
Current study HOPE study
(n = 92) (n = 4,645)
Age (yrs) 64.0 ( 12.2 66 ( 7
BMI 25.2 ( 4.5 28 ( 4
Female 33 (35.9%) 1,279 (27.5%)
Cardiovascular risk factors
History of stabilized heart failure 16 (17.4%) 3,691 (79.5%)
History of coronary artery disease 35 (38.0%) 2,410 (51.9%)
Myocardial infarction 17 (18.5%) 1,179 (25.4%)
CABG/PTCA 7 (7.6%) 2,045 (44.0%)
Stroke 6 (6.5%) 500 (10.8%)
Diabetes 30 (32.6%) 1,808 (38.9%)
Hypertension 59 (64.1%) 2,212 (47.6%)
Documented elevated total cholesterol level 39 (43.4%) 3,036 (65.4%)
Documented low HDL-C level 24 (26.1%) 842 (48.1%)
Current cigarette smoking 11 (12.5%) 645 (13.9%)
Medications
`-blocker 42 (50.6%) 1,820 (39.2%)
Calcium antagonists 33 (39.7%) 2,152 (46.3%)
Nitrates 45 (54.2%) -
Antiplatelet agents 55 (66.3%) 3,497 (75.3%)
Diuretics 20 (24.1%) 713 (15.3%)
Digoxin 4 (4.8%) -
Lipid-lowering agents 31 (37.3%) 1,318 (28.4%)
Antiarrhythmics 6 (7.2%) -
Anti-diabetes 23 (27.7%) -
BMI = body mass index; CABG = coronary artery bypass graft; PTCA = percutaneous transluminal coronary angioplasty; HDL-C = high-density
lipoprotein-cholesterol.
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Adverse events
Twenty-one patients (25.3%) had at least one adverse event,
of whom 19 individuals had only one adverse event and
two had two adverse events, giving a total of 23 reported
adverse events (Table 3). Of 83 patients, 12 discontinued the
study as a result of an adverse event and nine completed the
study despite an adverse event. The most common adverse
event was persistent dry cough. Other adverse events
included dizziness, hypotension, chest discomfort, headache
and numbness. No epigastric discomfort, skin rash, or
elevation of serum creatine was noted. There were no
significant changes in laboratory variables during the study.
DISCUSSION
ACE inhibitor-induced cough is the major problem with
these drugs in high-cardiovascular-risk patients. The
incidence of persistent dry cough varies in different
populations [11–14]. Only 7% of patients in the HOPE study
had dry cough [8]. However, in a northern Indian population,
the incidence was as high as 24.3% [11]. In this study, the
incidence of dry cough was 15.6%. There have been several
studies with a special focus on the possible genetic
polymorphism underlying tolerability, efficacy, and
incidence of adverse events [14–16]. However, in these
studies, ACE inhibitors were well tolerated and most patients
had cardiovascular protection benefits from their ACE
inhibitor. In addition, large-scale trials continue to support
their widespread clinical use.
In the HOPE study, the target maintenance dose was
10 mg/day, gradually titrated from one ramipril tablet
(2.5 mg) to four tablets. Compliance could be hampered if
patients hesitated to take all of their tablets at the same time.
Recently, ramipril has become available as a 10-mg tablet,
based on the HOPE study. However, according to our
study, some patients should still have titration from a lower
dose with regular monitoring.
Most patients in our study had at least two cardiovascular
risk factors and concomitant use of other cardiovascular
medication. The definition of adverse events was decided
Table 2. Patients completing the study and discontinuing
ramipril treatment (n = 92)
n (%)
Patients discontinuing treatment 21 (22.8%)
Patient’s request 9 (9.8%)
Adverse effects 12 (13.0%)
Patients completing the entire protocol 71 (85.6%)
Reached and remained at 10 mg/day 18 (25.3%)
Failure to reach or remain at 10 mg/day 53 (74.6%)
Final dose 7.5 mg/day 20 (28.2%)
Final dose 5.0 mg/day 22 (30.9%)
Final dose 2.5 mg/day 11 (15.5%)
Table 3. Incidence of adverse events and influence of ramipril use (n = 83)
n (%) Discontinued Continued
Cough 13 (15.6%) 10 * 3
Dizziness 5 (6.0%) 2 * 3
Hypotension 2 (2.4%) 2 0
Chest discomfort 1 0 1
Epigastralgia 0 0 0
Rash 0 0 0
Elevated serum creatine 0 0 0
Headache 1 0 1
Thirst 0 0 0
Numbness 1 0 1
Edema 0 0 0
Nausea 0 0 0
Elevated serum potassium 0 0 0
Shock 0 0 0
Liver function impairment 0 0 0
Oral ulcer 0 0 0
Epistaxis 0 0 0
Total events 23 14 9
*Two patients suffered from both cough and dizziness.
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by the individual physician’s observation and judgment.
Notably, most laboratory values were kept within stable
levels throughout the study period.
Although efficacy parameters were not included in this
study, there were two major cardiovascular events in two
separate patients. Both patients had an episode of non-ST
elevation myocardial infarction, and were admitted to the
coronary care unit for intensive care. Most other patients
were able to tolerate their maintenance dose.
Study limitations
Several limitations of this study should be mentioned. First,
it was conducted at one institution. However, the number
of patients was sufficient to reflect real practice and the real
adverse event rate in our daily clinical practice. Second,
unlike the HOPE study, most patients in our study did not
have symptoms or signs of significant heart failure, and all
patients were given 2.5 mg/day as the initial dose. Third,
most patients were taking a combination of anti-hypertensive
agents concomitantly with ramipril. It is possible that blood
pressure would be relatively reduced, which makes titrating
ramipril difficult. However, the dose of ramipril was titrated
as tolerated if patients were stable and asymptomatic.
Conclusion
The ACE inhibitor ramipril was relatively well tolerated in
our study population. However, only one-quarter of our
patients could reach the target maintenance dose of 10 mg/
day. Persistent dry cough, dizziness, and hypotension were
the major concerns when prescribing ACE inhibitors to
these patients. About 15% of our patients discontinued
ramipril treatment because of these adverse events, which
is compatible with previous reports.
ACKNOWLEDGMENTS
We would like to thank Quei-Ju Lin and Nai-Won Kuo for
data collection and questionnaire assistance.
REFERENCES
1. Vuong AD, Annis LG. Ramipril for the prevention and
treatment of cardiovascular disease. Ann Pharmacother 2003;
37:412–9.
2. Warner GT, Perry CM. Ramipril: a review of its use in the
prevention of cardiovascular outcomes. Drugs 2002;62:
1381–405.
3. Kleinert S. HOPE for cardiovascular disease prevention with
ACE-inhibitor ramipril. Heart Outcomes Prevention
Evaluation. Lancet 1999;354:841.
4. Arnold JM, Yusuf S, Young J, et al. Prevention of heart failure
in patients in the Heart Outcomes Prevention Evaluation
(HOPE) Study. Circulation 2003;107:1284–90.
5. Gerstein HC. Reduction of cardiovascular events and
microvascular complications in diabetes with ACE inhibitor
treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev
2002;18:S82–5.
6. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-
converting enzyme inhibition on diabetic nephropathy.
N Engl J Med 1993;329:1456–62.
7. Carroll CA, Coen MM, Rymer MM. Assessment of the effect of
ramipril therapy on direct health care costs for first and
recurrent strokes in high-risk cardiovascular patients using
data from the Heart Outcomes Prevention Evaluation (HOPE)
study. Clin Ther 2003;25:1248–61.
8. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-
converting-enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med 2000;342:
145–53.
9. Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of
angiotensin II and interleukin 6 in human coronary
atherosclerotic plaques: potential implications for inflammation
and plaque instability. Circulation 2000;101:1372–8.
10. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-
converting enzyme inhibitors in cardiac and vascular
protection. Circulation 1994;90:2056–69.
11. Singh NP, Uppal M, Anuradha S, et al. Angiotensin converting
enzyme inhibitors and cough — a north Indian study. J Assoc
Physicians India 1998;46:448–51.
12. Wu N, Zhu JR, Chen KA. Tolerability of ramipril 10 mg/day
in high-risk cardiovascular Chinese patients. Clin Drug Invest
2002;22:771–81.
13. Carre A, Vasmant D, Elmalem J, et al. Tolerability of ramipril
in a multicenter study of mild-to-moderate hypertension in
general practice. J Cardiovasc Pharmacol 1991;18:S141–3.
14. Mukae S, Itoh S, Aoki S, et al. Association of polymorphisms
of the renin-angiotensin system and bradykinin B2 receptor
with ACE-inhibitor-related cough. J Hum Hypertens 2002;16:
857–63.
15. Lee YJ, Tsai JC. Angiotensin-converting enzyme gene
insertion/deletion, not bradykinin B2 receptor -58T/C gene
polymorphism, associated with angiotensin-converting
enzyme inhibitor-related cough in Chinese female patients
with non-insulin-dependent diabetes mellitus. Metabolism
2001;50:1346–50.
16. Furuya K, Yamaguchi E, Hirabayashi T, et al. Angiotensin-I-
converting enzyme gene polymorphism and susceptibility to
cough. Lancet 1994;343:354.
17. Ding PY, Hu OY, Pool PE, et al. Does Chinese ethnicity affect
the pharmacokinetics and pharmacodynamics of angiotensin-
converting enzyme inhibitors? J Hum Hypertens 2000;14:
163–70.
516 Kaohsiung J Med Sci November 2005 • Vol 21 • No 11
